CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
bevacizumab [Avastin] +2 moredrug
Likely dose
bevacizumab [Avastin] 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00520403
NCT00520403Phase 2Completed
CompareCT.gov

An Open-label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Standard Therapy on Progression-free Survival in Patients With Metastatic Renal Cell Cancer.

Hoffmann-La Roche·interventional·Posted Aug 24, 2007·Updated Oct 13, 2014

In Brief

A Phase 2 clinical trial evaluating bevacizumab [Avastin], Interferon alfa-2a, and 1 other intervention for Renal Cell Cancer. Completed, enrolled 25 participants across 16 sites.

Detailed Summary

This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer. Patients will receive Avastin (15mg/kg iv) every 3 weeks, interferon alfa-2a 3 times weekly (3 Mio IU sc escalating to 18 Mio sc) and vinblastine (0.1mg/kg iv) every 3 weeks. The anticipated time on study treatment is until tumor progression, and the target sample size is 100-500 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Cancer
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 24, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.9 years ago

Interventions

bevacizumab [Avastin]drug

15mg/kg iv every 3 weeks

Interferon alfa-2adrug

3 MioIU sc escalating to 18 MioIU sc, 3 times weekly

Vinblastinedrug

0.1mg/kg iv every 3 weeks